US FDA gives first stem cell trial the green light, again
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has lifted a clinical hold and given Geron the green light to move its stem cell-derived therapy GRNOPC1 into what the California-based company says would be the world’s first clinical trial of an embryonic stem cell-based therapy in man1. The move meets with a previously announced timeline for when the hold would be removed.